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The relationship between oral and systemic health is not a new concept; rather, it is a dynamic concept 
that is continually reassessed. Acceptance of the oral-systemic link by the mainstream medical and 
dental communities has had its ups and downs through the years, not only due to questions of its 
scientific validity, but also because of the difficulty in finding indisputable evidence to substantiate such 
an association. 
This review explores the plausible biological mechanistic links between periodontal diseases and four 
common systemic diseases/conditions: cardiovascular disease, diabetes, respiratory diseases, and 
adverse pregnancy outcomes—all of which are associated with morbidity, mortality, and economic 
burden. The association between periodontal diseases and other systemic diseases/conditions, such as 
cancer, osteoporosis, metabolic syndrome, neurodegenerative diseases, and autoimmune diseases is 
also applicable; however, the evidence is still preliminary, and further research is warranted to better 




Biologically Plausible Mechanisms That Demonstrate a Link 
Van Dyke and van Winklehoff1 proposed two simultaneously occurring and interrelated biologically 
plausible mechanisms to explain the link between periodontal diseases and systemic diseases: the 
infectious pathway and the inflammatory pathway. The infectious pathway postulates that the direct 
invasion of oral microbes through the ulcerated and inflamed subgingival pocket epithelium 
subsequently leads to transient bacteremia. From there, the oral microbes systemically metastasize and 
infect nonoral sites (Figure 1). 
In contrast, the inflammatory pathway is highlighted by the spread of inflammatory mediators—not the 
bacteria or their byproducts—beyond the periodontium (Figure 2). These mediators subsequently 
induce and/or intensify the systemic inflammation, which then contributes to systemic diseases in 
susceptible individuals. These two fundamental pathways are the basis to understanding the 






In a classic study that investigated the relationship between oral health and cardiovascular disease, 
Mattila et al2 revealed a strong association between poor oral health and cardiovascular diseases, 
independent of other known cardiovascular risk factors such as age, social class, smoking, serum lipid 
concentrations, and presence of diabetes. This pivotal study included hundreds of other articles that 
corroborated a strong association between the two.3 As such, periodontal diseases are now recognized 
as risk factors for atherosclerotic vascular disease, which is the main cause of cardiovascular disease. 
The link between periodontal diseases and cardiovascular disease can be explained by both the 
infectious and the inflammatory pathways. In the infectious pathway, periodontopathic pathogens 
breach through the inflamed and ulcerated pocket epithelium, travel directly to the endothelial walls of 
blood vessels, and disrupt the integrity and the function of endothelial cells. This triggers several events 
simultaneously. First, platelets are activated, which initiates a cascade of events that leads to the 
formation of a thrombus at the site of injury. Second, leukocytes recruited to the site of injury release 
pro-inflammatory cytokines, reactive oxygen species, and tissue-degrading proteinases. A prolonged and 
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sustained release of inflammatory mediators at the site of injury subsequently amplifies the 
inflammatory response and further exacerbates vascular pathology. Several studies support the direct 
infectious nature of oral microbes as playing a direct role in periodontal diseases and atherosclerosis. 
Pollreisz et al4 found that invasive Porphyromonas gingivalis induce monocyte migration, which leads to 
elevated production of the pro-inflammatory mediators, IL-6, and TNF-α. Furthermore, in a study of 
atherosclerotic plaque and carotid endarterectomy samples from patients with atherosclerosis, Ford et 
al5 found that P. gingivalis was present in 100% of the samples while 84% of samples tested positive 
for Fusobacterium nucleatum and 48% of samples tested positive for Tannerella forsythia. In a different 
study, Bullon et al6 obtained blood samples from a group of 38 patients with periodontitis, and found 
that the lipopolysaccharide of P. gingivalis directly induced damage to the mitochondria of host 
fibroblasts, which led to an excessive production of reactive oxygen species by damaged fibroblasts. 
Overproduction of reactive oxygen species leads to oxidative stress, which is one of the many 
pathophysiological mechanisms of cardiovascular disease. Taking all these studies together, it seems 
biologically likely that invasive oral microbes have pro-atherogenic effects, which can serve as the basis 
of the infectious pathway between periodontal diseases and atherosclerosis. 
In contrast, the inflammatory pathway is highlighted by the role inflammatory mediators play in 
initiating and propagating the atherogenic process and endothelial dysfunction. As the periodontally 
derived inflammatory response intensifies, inflammation spreads beyond the periodontium to trigger 
the systemic inflammatory response. This is characterized by an elevated production of pro-
inflammatory mediators such as IL-1, IL-6, and TNF-α. The ensuing spike in circulating cytokines and 
inflammatory mediators provoke the liver to produce fibrinogen and C-reactive protein, which 
contribute to systemic inflammation, injury to the vascular endothelium, and formation of the 
atheroma. Several investigations have added credence to the inflammatory pathway as contributing to 
the atherogenic process.7-9 
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Overall, a preponderance of evidence supports the effectiveness of periodontal intervention in reducing 
the incidence of cardiovascular events. In a randomized controlled clinical trial composed of 120 
patients with periodontitis, Tonetti et al8 found that individuals who received intensive full-mouth 
subgingival plaque removal (test group) exhibited improved endothelial function, as measured by the 
vasodilation of the brachial artery (flow-mediated dilatation), compared to subjects who only received 
supra-gingival scaling (control group). Similarly, in a meta-analysis conducted by Teeuw et 
al,9 periodontal therapy was associated with improved endothelial function and reduced the 
inflammatory, thrombotic (fibrinogen), and metabolic (LDL, triglycerides) biomarkers associated with 
cardiovascular disease. 
Diabetes 
Currently, there is little evidence that invasive oral microbes influence glycemic control. In fact, evidence 
suggests that diabetes does not change the oral microbiota.10 Instead, a chronic dysregulated immune 
system and an imbalance of cytokines—characterized by increased production of pro-inflammatory 
mediators—is central to the pathogenesis of diabetes and its associated complications.11 In patients 
with poorly controlled diabetes, the resulting systemic inflammation is mediated by the elevated 
production of advanced glycation end products (AGE), which are protein molecules that undergo an 
irreversible, nonenzymatic glycation reaction. This reactive process, in turn, alters the structure and the 
function of the affected protein molecules. Increased accumulation of glycated proteins in the tissue 
disturbs normal tissue remodeling and interferes with normal wound healing. Moreover, AGE can bind 
to surface receptors, known as receptors for advanced glycation end products (RAGE), found on 
macrophages and other immune cells. When this interaction occurs, a potent inflammatory cascade is 
triggered that further amplifies tissue destruction, exacerbates the inflammatory response, blocks 
normal tissue repair, and limits self-resolution of inflammation. 
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When periodontitis co-exists with diabetes, periodontopathic bacteria trigger the host immune cells to 
release elevated levels of pro-inflammatory mediators IL-1, IL-6, and TNF-α. The release of pro-
inflammatory mediators not only initiates and sustains an intense and exaggerated systemic 
inflammatory response, but also downregulates insulin receptors at the end-target organ level, thereby 
leading to increased insulin resistance, reduced uptake of glucose into the cell, and a disruption in 
glycemic control. At the same time, the excessive formation and accumulation of AGE, as a result of 
irreversible glycation of proteins such as collagen, results in diabetic complications, interferes with 
collagen remodeling, impairs proper wound healing, and amplifies neutrophil response to periodontal 
pathogens. The inflammatory pathways are thus further intensified, and the expression of tissue-
degrading enzymes, such as metalloproteinases, is promoted. As such, the combined pathologic 
interactions of diabetes and periodontitis are akin to an unrelenting vicious cycle that incites and 
intensifies the inflammatory process, drastically disrupting the immune response and inevitably leading 




Despite a plausible link between the two, there is dueling evidence regarding the effectiveness of 
periodontal intervention in glycemic control. In a randomized controlled clinical trial involving 60 
subjects with diabetes and periodontitis, Koromantzos et al12 found that the subjects who received 
periodontal intervention at baseline (test group) exhibited statistically significant reductions in HbA1c 
levels compared with subjects who did not receive treatment at baseline (control group) at the end of 
the 6-month trial. In contrast, in a multi-centered, randomized clinical trial evaluating 514 subjects with 
diabetes and periodontitis, Engebretson et al13 found no statistically significant differences in changes of 
the HbA1c levels between the test group (periodontal treatment group) and the control group (non-
treatment group) at 6-month follow-up. These findings are consistent with another randomized 
controlled clinical trial that did not show a significant decrease in HbA1c levels between the test 
(periodontal treatment group) and the control groups (non-treatment group) at a 3-month follow-
up.14 The differing conclusions indicate that the existing evidence is still insufficient to either support or 
refute whether periodontal therapy can effectively improve glycemic control, and underscore the need 
for additional research. Nevertheless, numerous investigations agree that periodontal intervention leads 
to improvements in several critical periodontal parameters, such as bleeding on probing, pocket depths, 





The oral cavity may be a source of respiratory diseases, such as chronic obstructive pulmonary disease 
(COPD) or aspiration pneumonia in those with compromised immune systems. Among individuals with 
compromised immune systems, impaired protective cough reflexes, or those requiring mechanical 
ventilation, the risk of aspirating oral bacteria and developing respiratory diseases is elevated. 
In an attempt to link periodontal diseases with respiratory disease, Scannapieco15 outlined four 
biologically plausible mechanisms. One is consistent with the infectious pathway: aspiration of bacteria 
either commensal to the oral cavity—such as P. 
gingivalis and Aggregatibacter actinomycetemcomitans—or respiratory pathogens that colonize the oral 
tissues—such as Streptococcus pneumoniae and Haemophilus influenza—directly leads to respiratory 
infection. The second mechanism is consistent with the inflammatory pathway: cytokines from 
periodontal tissues damage respiratory epithelium and promote infection. The third and the fourth 
mechanisms focus on the microbially derived enzymes that degrade the actions of the protective 
salivary pellicle either on the mucosal surface, which blocks the clearance of pathogenic bacteria from 
the mucosal surface, or on the pathogens themselves, which facilitates the adhesion of pathogenic 
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bacterial to the mucosal surface. While it is difficult to speculate which of these mechanisms mediate 
the link between periodontal diseases and respiratory disorders, it is possible that either a single 
mechanism or a combination of several mechanisms plays a role in this association. 
Periodontal intervention may be effective in reducing the risk of respiratory diseases, such as 
pneumonia, among high-risk individuals (especially those living in assisted-living homes or intensive care 
units). In a systematic review investigating the effectiveness of periodontal intervention in reducing the 
risk of pneumonia and COPD in high-risk populations, Scannapieco et al16 found that dental treatment 
and a oral hygiene regimen focused on better plaque control were associated with a 40% reduction in 
the incidence of nosocomial pneumonia. In another systematic review, the investigators found good 
evidence that oral hygiene and frequent professional intervention reduced the risk of experiencing 
respiratory diseases among high-risk populations.17 
Adverse Pregnancy Outcomes 
Maternal age, smoking status, alcohol consumption, poor nutrition, and stress are known risk factors for 
adverse pregnancy outcomes, which are defined by preterm birth (< 37 weeks) and low birth weight 
(<2500 g). In addition, evidence has emerged implicating periodontal diseases asa significant risk factor 
for adverse pregnancy outcomes.18 
Both the infectious pathway and/or the inflammatory pathway may explain the link. On the one hand, 
P.gingivalis and A. actinomycetemcomitans have been detected in the amniotic fluid of pregnant 
women with periodontitis.19 Additionally, F. nucleatum has been frequently found in the amniotic fluid 
of premature births with intact membranes.20,21 Hence, it is conceivable that systemic exposure to the 
periodontal microbiota may be sufficient to trigger an adverse pregnancy outcome. On the other hand, 
as it relates to the inflammatory pathway, maternal exposure to periodontal infection induces an 
inflammatory response in the periodontal tissue, which systemically disseminates and stimulates the 
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production and release of pro-inflammatory mediators, such as IL‐1, IL‐6, TNF‐α, prostaglandins, and 
PGE2, in systemic circulation. Higher cytokine levels have been detected in mothers who deliver 
preterm.22 Consequently, higher cytokine levels may initiate premature uterine contractions, which 
ultimately leads to preterm labor.23 
Studies agree that nonsurgical periodontal intervention in pregnant mothers consistently lead to 
improvements in periodontal parameters, such as reductions in probing depths, gingival bleeding, and 
inflammatory mediators in the gingival crevicular fluid.24,25 Nevertheless, the evidence linking 
nonsurgical periodontal intervention to reducing adverse pregnancy outcomes is contradictory. Several 
studies have found that periodontal intervention had a negligible effect in reducing the risk of adverse 
pregnancy outcomes. In a large, multi-centered, randomized control clinical trial involving 823 pregnant 
women with periodontitis, Michaelowicz et al26 found that nonsurgical periodontal treatment before 21 
weeks of gestation did not reduce the risk of an adverse pregnancy outcome. In other words, although 
safe to perform on pregnant women, nonsurgical periodontal intervention did not significantly alter 
rates of preterm labor, low birth weight, or fetal growth restriction. This corroborates findings from 
another randomized controlled trial composed of303 pregnancy women with periodontitis.27 The results 
from this study demonstrated that while subjects who received comprehensive periodontal treatment 
including multiple rounds of scaling and root planing, oral hygiene instructions, and frequent 
maintenance visits (the test group) and subjects who received only one session of supra-gingival scaling 
and oral hygiene instructions during pregnancy (the control group) both exhibited improvements in 
periodontal health, there was no significant differences between the groups in the occurrence of 
adverse pregnancy outcomes. In contrast, a randomized clinical trial conducted by Lopez et al28 showed 
that periodontal intervention significantly reduced the risk of adverse pregnancy outcomes compared 
with the non-treatment group. In spite of the lack of unequivocal evidence to confirm the effectiveness 
of nonsurgical periodontal intervention in reducing the risk of adverse pregnancy outcomes, the 
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periodontal treatment in pregnant women is necessary to control periodontal infection and 
accompanying inflammation. 
Conclusion 
The available evidence points to biologically plausible links between periodontal diseases and 
cardiovascular disease, diabetes, respiratory diseases, and adverse pregnancy outcomes. Furthermore, 
current data corroborate that periodontal intervention may lead to positive outcomes in achieving 
improved oral health and in reducing the risks associated with systemic conditions. Yet, in spite of 
establishing probable links between periodontal diseases and these systemic diseases, there is still a 
need for further long-term interventional studies. Ideally, future studies should implement more 
standardized methodologies that permit a better understanding of whether the stated benefits of 
periodontal treatment translate into a reduction in incidence of these systemic events. 
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